Key result
QHRD106 improves cerebral blood flow and prolongs bradykinin changes versus UKN with good safety.
Why the study?
This study assessed the pharmacokinetics, pharmacodynamics, and safety of QHRD106 and compared it with urinary kallindinogenase in healthy volunteers.
Does QHRD106 demonstrate favorable pharmacokinetics, pharmacodynamics, and safety compared to placebo or urinary kallindinogenase in healthy volunteers?
RCT (n=130)
Double-blind and Open-label
Randomized
Does QHRD106 demonstrate favorable pharmacokinetics, pharmacodynamics, and safety compared to placebo or urinary kallindinogenase in healthy volunteers?
QHRD106 is a safe, long-acting kallikrein drug that improves cerebral blood flow in healthy volunteers, providing initial evidence for its potential use in ischemic stroke.
Answers are grounded in this paper and cite their sources.
QHRD106 shows favorable PK/PD and boosts cerebral blood flow in volunteers; extends early RCT data and supports trials in ischemic stroke.
BACKGROUND: This study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers. METHODS: This study comprised a randomized, double-blind, placebo-controlled, single-dose escalation phase and an open-label, multiple-dose escalation phase. Ninety-four subjects received intramuscular injections of QHRD106/placebo only once and 30 subjects received QHRD106 four times. Six subjects received 0.15 PNA units UKN intravenously for 7 d. PK and PD analysis were conducted by using a electrochemiluminescent assay and a liquid chromatography/mass spectrometry methodology, respectively. Cerebral circulation was assessed by the magnetic resonance imaging system. RESULTS: QHRD106 exhibited a slow absorption profile in the human body. Compared to UKN, QHRD106-induced changes in bradykinin concentration later, but with a noticeably prolonged duration. Compared to baseline, cerebral blood flow exhibited a significant improvement on d 7 after a single dose of 18,900 IU and an improvement from d 2 to d 14 after multiple doses of 8400 IU of QHRD106. QHRD106 appeared generally good safety and no severe adverse events occurred in all the groups. CONCLUSIONS: This study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug. REGISTRATION: This study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) conducted an RCT in Healthy volunteers (n=130). QHRD106 vs. Placebo and urinary kallindinogenase (UKN) was evaluated on Pharmacokinetics, pharmacodynamics, and safety. QHRD106 demonstrated a slow absorption profile, prolonged bradykinin concentration changes compared to UKN, and significantly improved cerebral blood flow with a generally good safety profile.
Synapse has enriched 10 related papers. Consider them for comparative context: